Ipramol Steri-Neb

Ipratropium bromide and salbutamol, the active ingredients in Ipramol Steri-Neb, are bronchodilators presented as a nebulizer solution for inhalation use. They treat bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma, providing rapid relief of airway constriction in patients who require inhaled therapy.

GNH USA supplies Ipramol Steri-Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipramol Steri-Neb is a combination bronchodilator used in the respiratory disease pathway to relieve airway narrowing.

- COPD bronchospasm: improves airflow and reduces dyspnea in chronic obstructive pulmonary disease patients. - Asthma bronchospasm: provides rapid bronchodilation during acute asthma attacks. - Exercise‑induced bronchospasm: helps prevent airway constriction triggered by physical activity.

Ipramol Steri-Neb may cause a range of adverse reactions following inhalation.

Common Side Effects: - Cough or throat irritation - Dry mouth or throat - Tremor of the hands or limbs - Palpitations or mild tachycardia - Headache - Nausea

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe tachyarrhythmia - Hypotension - Allergic reactions such as rash, angioedema, or anaphylaxis - Hyperglycemia in susceptible individuals - Cardiovascular events (e.g., myocardial ischemia)

Before using Ipramol Steri-Neb, consider the following safety measures.

- Cardiac assessment: monitor for tachycardia or arrhythmias, especially in patients with heart disease. - Diabetes monitoring: observe blood glucose levels as salbutamol may raise glucose. - Thyroid disease: use caution in hyperthyroid patients due to potential tachycardia. - Pregnancy and lactation: discuss risks with a healthcare professional; data are limited. - Pediatric use: dose and frequency should be determined by a prescriber. - Store at ambient temperature: keep the solution below 25 °C, protect from light and moisture, and retain in the original container.

Ipramol Steri-Neb can interact with other medications that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): can increase the risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Selective β‑blockers: may reduce efficacy of salbutamol. - Theophylline: combined use may enhance tachycardia. - Other anticholinergic agents: may increase anticholinergic burden. - Diuretics: monitor electrolyte balance and blood pressure.